Researchers from the University of Pittsburg School of Medicine are utilizing mesenchymal stem cells [MSCs] to develop a treatment for Idiopathic Pulmonary Fibrosis (IPF). MSCs possess valuable properties that make them particularly suitable for potential treatments – chief amongst them are; their plasticity [ability to differentiate into a particular tissue type], their anti-inflammatory capabilities and, their immunomodulatory properties. Currently, there are five Phase 1 clinical trials registered utilizing MSCs to treat IPF.
Researchers at University of Miami Health System receive FDA approval for the first U.S. clinical trial using mesenchymal stem cells to treat idiopathic pulmonary fibrosis. Mesenchymal stem cells are multipotent adult stem cells that can be isolated from bone marrow, teeth, and fat. Mesenchymal stem cells have demonstrated the ability to differentiate into bone, cartilage, cardiomyocites, muscle, neuronal cells, insulin producing pancreatic beta cells and more.